8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 1, 2026·SEC
Material company update
Mar 6, 2026·SEC
Clover Health Investments, Corp.(CLOV)Earnings, Financials & Key Ratios
CLOV•NASDAQ•Insurance & Managed Care
$2.68
$1.37B mkt cap·Price updated May 6, 2026
AboutClover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.Show more
- Revenue$1.92B+40.3%
- Combined Ratio104.44%+1.1%
- Net Income-$86M-98.9%
- Return on Equity-26.33%-92.1%
- Medical Cost Ratio81.5%+11.1%
- Operating Margin-4.44%-33.2%
- Net Margin-4.45%-41.7%
- ROA-15.25%-104.2%
- Equity / Assets57.06%-2.9%
- Book Value per Share0.60-14.3%
- Tangible BV/Share0.59-14.4%
CLOV Key Insights
Clover Health Investments, Corp. (CLOV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗High loss ratio of 81.5%
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CLOV Price & Volume
Clover Health Investments, Corp. (CLOV) stock price & volume — 10-year historical chart
Loading chart...
CLOV Growth Metrics
Clover Health Investments, Corp. (CLOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years23.39%
3 Years20.62%
TTM48.75%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-126.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-102.31%
Return on Capital
10 Years-99.35%
5 Years-68.96%
3 Years-32.59%
Last Year-24.46%
CLOV Recent Earnings
Clover Health Investments, Corp. (CLOV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 26, 2026EPS
$0.05
Est $0.10
+51.0%
Revenue
$488M
Est $467M
+4.4%
Q4 2025
Nov 4, 2025EPS
$0.05
Est $0.02
-350.0%
Revenue
$497M
Est $467M
+6.3%
Q3 2025
Aug 5, 2025EPS
$0.03
Est $0.03
+0.0%
Revenue
$478M
Est $468M
+2.0%
Q2 2025
May 6, 2025EPS
$0.05
Est $0.07
+171.4%
Revenue
$462M
Est $467M
-1.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.05vs $0.10+51.0% | $488Mvs $467M+4.4% |
| Q4 2025 | Nov 4, 2025 | $0.05vs $0.02-350.0% | $497Mvs $467M+6.3% |
| Q3 2025 | Aug 5, 2025 | $0.03vs $0.03+0.0% | $478Mvs $468M+2.0% |
| Q2 2025 | May 6, 2025 | $0.05vs $0.07+171.4% | $462Mvs $467M-1.0% |
Based on last 12 quarters of dataView full earnings history →
CLOV Peer Comparison
Clover Health Investments, Corp. (CLOV) competitors in Tech-Enabled Health Plans — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HUM | 29.57B | 246.33 | 25.03 | 10.06% | 0.82% | 6.17% | 0.73 | |
 CVS | 111.32B | 86.86 | 62.49 | 7.85% | 0.72% | 3.86% | 1.24 | |
 ELV | 81.37B | 374.71 | 14.92 | 12.62% | 2.62% | 11.92% | 0.75 | |
 CNC | 27.31B | 55.32 | -4.06 | 19.44% | -3.25% | -28.6% | 0.94 | |
 MOH | 10.28B | 197.44 | 22.13 | 11.75% | 0.42% | 4.44% | 0.97 | |
 ALHC | 3.71B | 18.14 | -4902.70 | 46.06% | 0.47% | 11.5% | 1.89 | |
 OSCR | 5.14B | 19.84 | -11.74 | 27.5% | -0.3% | -3.26% | 0.44 | |
 BHVN | 1.06B | 10.04 | -1.46 | -8.66% | 5.36 |
Compare CLOV vs Peers
Clover Health Investments, Corp. (CLOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLOV Income Statement
Clover Health Investments, Corp. (CLOV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 281.02M | 462.27M | 672.89M | 1.47B | 1.1B | 1.26B | 1.37B | 1.92B | 2.21B |
| Revenue Growth % | - | 64.49% | 45.56% | 118.76% | -25.51% | 14.96% | 8.77% | 40.34% | 48.75% |
| Medical Costs & Claims | 0 | 449.7M | 590.08M | 1.55B | 993.07M | 1B | 1.01B | 1.57B | 1.27B |
| Medical Cost Ratio % | 0% | 97.28% | 87.69% | 105.38% | 90.56% | 79.7% | 73.39% | 81.5% | 57.53% |
| Gross Profit | 281.02M▲ 0% | 12.56M▼ 95.5% | 82.81M▲ 559.0% | -79.18M▼ 195.6% | 103.48M▲ 230.7% | 255.95M▲ 147.3% | 364.8M▲ 42.5% | 355.88M▼ 2.4% | 939.14M▲ 0% |
| Gross Margin % | 100% | 2.72% | 12.31% | -5.38% | 9.44% | 20.3% | 26.61% | 18.49% | 42.47% |
| Gross Profit Growth % | - | -95.53% | 559.02% | -195.62% | 230.68% | 147.35% | 42.53% | -2.45% | - |
| Operating Expenses | 476M | 195.76M | 175.51M | 557.81M | 390.14M | 461.28M | 410.55M | 441.43M | 996.06M |
| OpEx / Revenue % | 169.38% | 42.35% | 26.08% | 37.89% | 35.58% | 36.59% | 29.94% | 22.94% | 45.05% |
| Depreciation & Amortization | 185.8M | 551K | 555K | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M | 1.74M |
| Combined Ratio % | 169.38% | 139.63% | 113.78% | 143.27% | 126.14% | 116.29% | 103.34% | 104.44% | 102.57% |
| Operating Income | -185.8M▲ 0% | -183.2M▲ 1.4% | -92.71M▲ 49.4% | -636.99M▼ 587.1% | -286.66M▲ 55.0% | -205.33M▲ 28.4% | -45.75M▲ 77.7% | -85.53M▼ 87.0% | -56.92M▲ 0% |
| Operating Margin % | -66.11% | -39.63% | -13.78% | -43.27% | -26.14% | -16.29% | -3.34% | -4.44% | -2.57% |
| Operating Income Growth % | - | 1.4% | 49.4% | -587.1% | 55% | 28.37% | 77.72% | -86.95% | - |
| EBITDA | 0 | -182.65M | -92.15M | -635.75M | -285.48M | -202.82M | -44.42M | -83.84M | -55.19M |
| EBITDA Margin % | 0% | -39.51% | -13.69% | -43.19% | -26.03% | -16.09% | -3.24% | -4.36% | -2.5% |
| Interest Expense | 0 | 39.07M | 57.11M | 16.91M | 1.36M | 7K | 0 | 0 | 0 |
| Non-Operating Income | 186.67M | 141.47M | -13.42M | -66.15M | -33.44M | 4.81M | 517K | 20K | 20K |
| Pretax Income | -201.93M▲ 0% | -363.74M▼ 80.1% | -136.39M▲ 62.5% | -587.76M▼ 330.9% | -254.58M▲ 56.7% | -210.15M▲ 17.5% | -46.27M▲ 78.0% | -85.55M▼ 84.9% | -56.94M▲ 0% |
| Pretax Margin % | -71.85% | -78.69% | -20.27% | -39.93% | -23.22% | -16.67% | -3.37% | -4.45% | -2.58% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -201.93M▲ 0% | -363.74M▼ 80.1% | -136.39M▲ 62.5% | -587.76M▼ 330.9% | -339.57M▲ 42.2% | -213.36M▲ 37.2% | -43.01M▲ 79.8% | -85.55M▼ 98.9% | -56.94M▲ 0% |
| Net Margin % | -71.85% | -78.69% | -20.27% | -39.93% | -30.97% | -16.93% | -3.14% | -4.45% | -2.58% |
| Net Income Growth % | - | -80.13% | 62.5% | -330.93% | 42.23% | 37.17% | 79.84% | -98.91% | -126.74% |
| EPS (Diluted) | -4.81▲ 0% | -0.90▲ 81.3% | -0.23▲ 74.4% | -1.25▼ 443.5% | -0.71▲ 43.2% | -0.45▲ 36.6% | -0.09▲ 80.5% | -0.17▼ 93.6% | -0.11▲ 0% |
| EPS Growth % | - | 81.29% | 74.44% | -443.48% | 43.2% | 36.62% | 80.49% | -93.62% | -102.31% |
| EPS (Basic) | -4.81 | -0.90 | -0.23 | -1.25 | -0.71 | -0.45 | -0.09 | -0.17 | - |
| Diluted Shares Outstanding | 42.01M | 404.44M | 404.44M | 470.85M | 476.24M | 482.18M | 490.02M | 517.24M | 522.18M |
CLOV Balance Sheet
Clover Health Investments, Corp. (CLOV) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 210.6M | 100.35K | 267.25M | 950.8M | 808.62M | 570.67M | 580.74M | 541.01M | 697.73M |
| Asset Growth % | - | -99.95% | 266230.5% | 255.77% | -14.95% | -29.43% | 1.76% | -6.84% | -16.32% |
| Total Investment Assets | 0 | 0 | 58.76M | 491.23M | 369.08M | 240.82M | 228.72M | 204.14M | 4M |
| Long-Term Investments | 0 | 0 | 54.39M | 175.94M | 138.11M | 121M | 201.72M | 187.09M | 757.87M |
| Short-Term Investments | 0 | 0 | 4.36M | 315.29M | 230.97M | 119.82M | 27M | 17.05M | 4.29M |
| Total Current Assets | 75.4M | 0 | 189.78M | 752.55M | 625M | 427.97M | 343.12M | 307.86M | 448.02M |
| Cash & Equivalents | 75.4M | 0 | 92.35M | 299.97M | 103.79M | 116.41M | 194.54M | 78.3M | 173.26M |
| Receivables | 0 | 0 | 84.94M | 109.42M | 167.54M | 86.24M | 92.79M | 158.74M | 393.6M |
| Other Current Assets | 0 | 0 | 299K | 13.18M | 104.55M | 91.08M | 15.62M | 53.77M | 270.46M |
| Goodwill & Intangibles | 2.99M | 0 | 4.23M | 4.23M | 20M | 2.99M | 2.99M | 2.99M | 11.96M |
| Goodwill | 0 | 0 | 0 | 0 | 11.75M | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.99M | 0 | 4.23M | 4.23M | 8.25M | 2.99M | 2.99M | 2.99M | 2.99M |
| PP&E (Net) | 3.21M | 0 | 9.96M | 7.65M | 9.78M | 5.08M | 5.31M | 6.38M | 6.9M |
| Other Assets | 128.99M | 100.35K | 8.88M | 10.43M | 15.73M | 13.63M | 27.6M | 36.69M | 37.57M |
| Total Liabilities | 265.42M | 117.98K | 880.45M | 411.49M | 451.73M | 284.28M | 239.6M | 232.31M | 358.3M |
| Total Debt | 49.25M | 0 | 138.36M | 27.83M | 5.86M | 4.66M | 0 | 0 | 0 |
| Net Debt | -26.15M | 0 | 46.01M | -272.14M | -97.93M | -111.74M | -194.54M | -78.3M | -173.26M |
| Long-Term Debt | 49.25M | 0 | 106.41M | 19.94M | 0 | 0 | 0 | 0 | 0 |
| Short-Term Debt | 0 | 0 | 20.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 6.03M | 117.98K | 164.23M | 372.62M | 431.51M | 261.12M | 213.52M | 208.82M | 336.58M |
| Accounts Payable | 0 | 0 | 30.67M | 28.13M | 32.45M | 37.18M | 34.56M | 153.25M | 0 |
| Deferred Revenue | 0 | 0 | 102.43M | 138.6M | 0 | 3.1M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | -102.42M | 8.99M | 81.57M | 61.12M | 22.56M | 55.57M | 336.58M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 210.15M | 0 | 603.46M | 14.1M | 16.19M | 20.16M | 26.08M | 23.48M | 21.72M |
| Total Equity | -54.83M▲ 0% | -17.63K▲ 100.0% | -613.19M▼ 3477825.2% | 539.32M▲ 188.0% | 356.89M▼ 33.8% | 286.39M▼ 19.8% | 341.14M▲ 19.1% | 308.7M▼ 9.5% | 339.43M▲ 0% |
| Equity Growth % | - | 99.97% | -3477825.25% | 187.95% | -33.83% | -19.75% | 19.12% | -9.51% | -2.93% |
| Shareholders Equity | -54.83M | -17.63K | -617.1M | 535.41M | 356.89M | 286.39M | 341.14M | 308.7M | 339.43M |
| Minority Interest | 0 | 0 | 3.9M | 3.9M | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -527.9M | -17.63K | -1.03B | -1.62B | -1.95B | -2.16B | -2.2B | -2.29B | -2.26B |
| Common Stock | 4K | 0 | 9K | 46K | 46K | 49K | 50K | 52K | 52K |
| Accumulated OCI | 0 | 0 | 10K | -1.93M | -9.37M | -2.37M | -1.58M | 528K | -672K |
| Return on Equity (ROE) | - | - | - | -108.98% | -75.78% | -66.34% | -13.71% | -26.33% | -17.08% |
| Return on Assets (ROA) | -95.88% | -345.27% | -102.03% | -96.51% | -38.6% | -30.94% | -7.47% | -15.25% | -9.6% |
| Equity / Assets | -26.03% | -17.57% | -229.44% | 56.72% | 44.14% | 50.19% | 58.74% | 57.06% | 48.65% |
| Debt / Equity | - | - | - | 0.05x | 0.02x | 0.02x | - | - | 0.00x |
| Book Value per Share | -1.31 | -0.00 | -1.52 | 1.15 | 0.75 | 0.59 | 0.70 | 0.60 | 0.65 |
| Tangible BV per Share | -1.38 | -0.00 | -1.53 | 1.14 | 0.71 | 0.59 | 0.69 | 0.59 | 0.64 |
CLOV Cash Flow Statement
Clover Health Investments, Corp. (CLOV) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -153.28M | -159.88M | -118.5M | -282.33M | -203.93M | -115.87M | 34.84M | -66.93M | -66.93M |
| Operating CF Growth % | - | -4.3% | 25.88% | -138.25% | 27.77% | 43.18% | 130.07% | -292.09% | 619.11% |
| Operating CF / Revenue % | -54.54% | -34.59% | -17.61% | -19.18% | -18.6% | -9.19% | 2.54% | -3.48% | -3.03% |
| Net Income | -201.93M | -363.74M | -136.39M | -587.76M | -339.57M | -213.36M | -43.01M | -85.55M | -56.94M |
| Depreciation & Amortization | 487K | 551K | 0 | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M | 1.74M |
| Stock-Based Compensation | 3.68M | 3.3M | 0 | 163.72M | 164.31M | 140.93M | 114.33M | 103.66M | 89.49M |
| Deferred Taxes | 0 | 0 | 0 | -66.09M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 9.51M | 167.7M | 42.35M | 13.88M | -27.49M | 9.48M | -50.66M | -2.53M | 73.83M |
| Working Capital Changes | 34.97M | 32.31M | -24.46M | 192.67M | -2.36M | -55.43M | 12.86M | -84.2M | -50.86M |
| Cash from Investing | 97.53M | -181.91M | 141.31M | -435.45M | 95.13M | 140.01M | 565K | 4.08M | -9.92M |
| Capital Expenditures | -1.48M | -23K | -693K | -723K | -4.47M | -584K | -1.56M | -2.04M | -2.71M |
| Acquisitions | 0 | -1.18M | 3.9M | 434.72M | -16.2M | 0 | 0 | 0 | 0 |
| Purchase of Investments | 0 | -505.55M | -174.32M | -876.25M | -369.65M | -175.57M | -201.24M | -205.1M | -212.84M |
| Sale/Maturity of Investments | 0 | 324.84M | 312.42M | 441.53M | 485.45M | 316.16M | 203.36M | 211.22M | 205.63M |
| Other Investing | 99M | 0 | 0 | -434.72M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 74.59M | 333.98M | 1.94M | 925.39M | -4.96M | -33.86M | -17.36M | -53.38M | -29.51M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -147K | -6.36M | -6.22M | -18.26M | -55.2M | -23.24M |
| Stock Issued | 0 | 601K | 1.75M | 289.92M | 1.4M | 1.15M | 902K | 1.81M | 1.6M |
| Debt Issuance (Net) | 1000K | 1000K | 1000K | -1000K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 44.83M | -363K | -957K | 666.55M | 0 | -28.79M | 0 | 0 | -7.86M |
| Net Change in Cash | 18.83M▲ 0% | -7.8M▼ 141.4% | 92.35M▲ 1283.2% | 207.62M▲ 124.8% | -113.75M▼ 154.8% | -9.72M▲ 91.5% | 18.05M▲ 285.7% | -116.24M▼ 744.0% | 17.83M▲ 0% |
| Exchange Rate Effect | 0 | 0 | 67.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 56.57M | 75.4M | 0 | 92.35M | 299.97M | 186.21M | 176.49M | 194.54M | 78.3M |
| Cash at End | 75.4M | 67.6M | 92.35M | 299.97M | 186.21M | 176.49M | 194.54M | 78.3M | 173.26M |
| Free Cash Flow | -154.76M▲ 0% | -159.9M▼ 3.3% | -119.19M▲ 25.5% | -283.05M▼ 137.5% | -208.39M▲ 26.4% | -116.45M▲ 44.1% | 33.29M▲ 128.6% | -68.98M▼ 307.2% | 54.54M▲ 0% |
| FCF Growth % | - | -3.32% | 25.46% | -137.48% | 26.38% | 44.12% | 128.59% | -307.21% | 728.44% |
| FCF Margin % | -55.07% | -34.59% | -17.71% | -19.23% | -19% | -9.24% | 2.43% | -3.58% | 2.47% |
| FCF per Share | -3.68 | -0.4 | -0.29 | -0.6 | -0.44 | -0.24 | 0.07 | -0.13 | -0.13 |
CLOV Key Ratios
Clover Health Investments, Corp. (CLOV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Combined Ratio | 139.63% | 113.78% | 143.27% | 126.14% | 116.29% | 103.34% | 104.44% | 102.57% |
| Medical Cost Ratio | 97.28% | 87.69% | 105.38% | 90.56% | 79.7% | 73.39% | 81.5% | 57.53% |
| Return on Equity (ROE) | - | - | -108.98% | -75.78% | -66.34% | -13.71% | -26.33% | -17.08% |
| Return on Assets (ROA) | -345.27% | -102.03% | -96.51% | -38.6% | -30.94% | -7.47% | -15.25% | -9.6% |
| Equity / Assets | -17.57% | -229.44% | 56.72% | 44.14% | 50.19% | 58.74% | 57.06% | 48.65% |
| Book Value / Share | -0 | -1.52 | 1.15 | 0.75 | 0.59 | 0.7 | 0.6 | 0.65 |
| Debt / Equity | - | - | 0.05x | 0.02x | 0.02x | - | - | 0.00x |
| Revenue Growth | 64.49% | 45.56% | 118.76% | -25.51% | 14.96% | 8.77% | 40.34% | 48.75% |
CLOV SEC Filings & Documents
Clover Health Investments, Corp. (CLOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLOV Frequently Asked Questions
Clover Health Investments, Corp. (CLOV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Clover Health Investments, Corp. (CLOV) grew revenue by 40.3% over the past year. This is strong growth.
Clover Health Investments, Corp. (CLOV) reported a net loss of $56.9M for fiscal year 2025.
Dividend & Returns
Clover Health Investments, Corp. (CLOV) has a return on equity (ROE) of -26.3%. Negative ROE indicates the company is unprofitable.
Industry Metrics
Clover Health Investments, Corp. (CLOV) has a combined ratio of 104.4%. A ratio above 100% means claims and expenses exceed premiums.
Explore More CLOV
Clover Health Investments, Corp. (CLOV) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates